22.04
price down icon1.78%   -0.40
pre-market  プレマーケット:  22.11   0.07   +0.32%
loading
前日終値:
$22.44
開ける:
$22.49
24時間の取引高:
36.84M
Relative Volume:
0.81
時価総額:
$125.00B
収益:
$63.63B
当期純損益:
$8.03B
株価収益率:
15.63
EPS:
1.41
ネットキャッシュフロー:
$9.84B
1週間 パフォーマンス:
-2.00%
1か月 パフォーマンス:
-14.31%
6か月 パフォーマンス:
-25.72%
1年 パフォーマンス:
-14.21%
1日の値動き範囲:
Value
$21.95
$22.68
1週間の範囲:
Value
$21.09
$22.93
52週間の値動き範囲:
Value
$20.91
$31.54

Pfizer Inc Stock (PFE) Company Profile

Name
名前
Pfizer Inc
Name
セクター
Healthcare (1155)
Name
電話
(212) 733-2323
Name
住所
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Name
職員
81,000
Name
Twitter
@Pfizer
Name
次回の収益日
2025-02-04
Name
最新のSEC提出書
Name
PFE's Discussions on Twitter

PFE を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Drug Manufacturers - General icon
PFE
Pfizer Inc
22.04 125.00B 63.63B 8.03B 9.84B 1.41
Drug Manufacturers - General icon
LLY
Lilly Eli Co
734.90 660.07B 45.04B 10.59B 414.30M 11.71
Drug Manufacturers - General icon
JNJ
Johnson Johnson
153.91 344.63B 89.33B 21.81B 18.06B 8.99
Drug Manufacturers - General icon
ABBV
Abbvie Inc
171.68 303.70B 56.33B 4.28B 17.83B 2.40
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
62.88 279.13B 42.09B 14.65B 10.11B 3.2833
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
109.58 216.43B 51.72B 11.94B 13.81B 5.88

Pfizer Inc Stock (PFE) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-10 再開されました BofA Securities Neutral
2024-11-15 開始されました Wolfe Research Underperform
2024-10-25 再開されました Citigroup Neutral
2024-10-17 開始されました Bernstein Mkt Perform
2024-08-07 アップグレード Daiwa Securities Neutral → Outperform
2024-03-22 ダウングレード Argus Buy → Hold
2024-02-23 開始されました Guggenheim Buy
2024-01-04 ダウングレード TD Cowen Outperform → Market Perform
2023-10-20 再開されました UBS Neutral
2023-10-16 アップグレード Jefferies Hold → Buy
2023-07-17 繰り返されました JP Morgan Neutral
2023-07-14 開始されました HSBC Securities Buy
2023-06-29 ダウングレード Credit Suisse Outperform → Neutral
2023-05-11 ダウングレード Daiwa Securities Outperform → Neutral
2023-03-06 開始されました Jefferies Hold
2023-02-07 アップグレード Daiwa Securities Neutral → Outperform
2023-01-26 ダウングレード UBS Buy → Neutral
2023-01-17 ダウングレード Wells Fargo Overweight → Equal Weight
2023-01-04 ダウングレード BofA Securities Buy → Neutral
2022-12-13 アップグレード Goldman Neutral → Buy
2022-11-18 開始されました Credit Suisse Outperform
2022-05-23 開始されました SVB Leerink Mkt Perform
2022-04-06 再開されました Morgan Stanley Equal-Weight
2022-01-05 アップグレード BofA Securities Neutral → Buy
2022-01-03 繰り返されました Bernstein Mkt Perform
2021-12-20 繰り返されました Cowen Outperform
2021-12-17 開始されました Goldman Neutral
2021-12-13 アップグレード UBS Neutral → Buy
2021-12-09 開始されました Wells Fargo Overweight
2021-11-19 開始されました BMO Capital Markets Outperform
2021-07-27 再開されました Truist Buy
2021-05-06 ダウングレード Mizuho Buy → Neutral
2021-04-07 再開されました RBC Capital Mkts Sector Perform
2021-02-04 アップグレード DZ Bank Hold → Buy
2020-12-16 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2020-11-19 再開されました Goldman Neutral
2020-11-10 再開されました Bernstein Mkt Perform
2020-10-12 ダウングレード Atlantic Equities Overweight → Neutral
2020-09-29 開始されました Berenberg Hold
2020-06-16 開始されました SVB Leerink Mkt Perform
2020-02-27 開始されました Barclays Equal Weight
2020-02-27 アップグレード Standpoint Research Hold → Buy
2020-02-06 開始されました Mizuho Buy
2020-01-07 開始されました RBC Capital Mkts Outperform
2019-10-17 再開されました BofA/Merrill Neutral
2019-07-30 ダウングレード BofA/Merrill Buy → Neutral
2019-07-30 ダウングレード Morgan Stanley Overweight → Equal-Weight
2019-06-04 再開されました Morgan Stanley Overweight
2019-02-20 再開されました Citigroup Neutral
2019-01-31 アップグレード Argus Hold → Buy
2019-01-31 アップグレード Credit Suisse Neutral → Outperform
2019-01-23 ダウングレード UBS Buy → Neutral
2018-12-11 ダウングレード JP Morgan Overweight → Neutral
2018-11-01 ダウングレード BMO Capital Markets Outperform → Market Perform
すべてを表示

Pfizer Inc (PFE) 最新ニュース

pulisher
03:36 AM

Henlius In David Versus Goliath Race With Pfizer For First PD-L1 ADC - insights.citeline.com

03:36 AM
pulisher
12:58 PM

Pfizer: Risks Priced In, Buy The Exceptional Valuation And Yield - Seeking Alpha

12:58 PM
pulisher
Apr 16, 2025

Lobbying Update: $20,000 of PFIZER INC lobbying was just disclosed - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

GSK, Pfizer Zantac Appeal Gets Tough Questions From Some Delaware Judges - Bloomberg.com

Apr 16, 2025
pulisher
Apr 16, 2025

Pfizer Says US CDC Panel Votes to Expand Recommendation for RSV Vaccine - MarketScreener

Apr 16, 2025
pulisher
Apr 16, 2025

Pfizer gets ACIP backing as it votes to expand RSV vaccine recommendation - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

ACIP Votes to Expand Recommendation for Pfizer’s RSV Vaccine ABRYSVO - Business Wire

Apr 16, 2025
pulisher
Apr 16, 2025

Pfizer: Tasty 7% Yield (NYSE:PFE) - Seeking Alpha

Apr 16, 2025
pulisher
Apr 16, 2025

What You Need to Know Ahead of Pfizer's Earnings Release - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Empyema Market Deep Research Report with Forecast by 2032 | Pfizer Inc.,Merck & Co., Inc.,GlaxoSmithKline plc - openPR.com

Apr 16, 2025
pulisher
Apr 16, 2025

Stomach Cancer Drugs Market Witness Significant Growth by 2025-2032 | Pfizer Inc., Eli Lilly and Company - openPR.com

Apr 16, 2025
pulisher
Apr 16, 2025

Tariff Turmoil, FDA’s Future, Pfizer’s Obesity Setback and CEO Salaries Revealed - BioSpace

Apr 16, 2025
pulisher
Apr 16, 2025

Neuropathic Pain Market Detailed In New Research Report 2025 | - openPR.com

Apr 16, 2025
pulisher
Apr 15, 2025

Why Pfizer Stock Topped the Market on Tuesday - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

Will Pfizer approach Viking Therapeutics with a buyout proposal? - TradingView

Apr 15, 2025
pulisher
Apr 15, 2025

Novavax Covid Vaccine Shows Milder Side Effects Than Pfizer-BioNTech's Shot: Study - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes (NASDAQ:VKTX) - Seeking Alpha

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer Halts Obesity Pill Development Amid Safety Concerns - Zacks Investment Research

Apr 15, 2025
pulisher
Apr 15, 2025

Bernstein reiterates Pfizer stock with $30 target post-drug axe - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Bernstein reiterates Pfizer stock with $30 target post-drug axe By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

TD Cowen Remains a Hold on Pfizer (PFE) - The Globe and Mail

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer (PFE) Gets a Hold from Bernstein - The Globe and Mail

Apr 15, 2025
pulisher
Apr 15, 2025

BofA keeps Neutral on Pfizer after danuglipron failure as core thesis unchanged - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer Ends Testing of Obesity Pill After Possible Liver Injury - El Paso Inc.

Apr 15, 2025
pulisher
Apr 15, 2025

Smaller obesity drugmakers jump after Pfizer scraps weight-loss pill - Yahoo Finance

Apr 15, 2025
pulisher
Apr 15, 2025

What You Need To Know Ahead Of Pfizer's Earnings Release - Barchart.com

Apr 15, 2025
pulisher
Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Is High-Yield Pfizer Stock Still a Buy After Scrapping Its Weight-Loss Pill? - The Motley Fool

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer scraps weight loss candidate after trial setback: What it means for the future of oral obesity drugs - munsifdaily.com

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer Halts Oral GLP-1 Drug Danuglipron Development Amid Liver Safety Concerns - geneonline.com

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer (PFE) Abandons Obesity Drug Trial Due to Safety Concerns - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Pfizer (PFE) Halts Trial of GLP-1 Pill Due to Safety Concerns - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Why Pfizer scrapped obesity pill development: Weight-loss drug market shares explored - financialexpress.com

Apr 15, 2025
pulisher
Apr 14, 2025

Pfizer Ends Development of Its Obesity Pill - Time Magazine

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer ends development of potential pill obesity treatment - CNN

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer to no longer develop weight loss pill - The San Joaquin Valley Sun

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer hits setback in obesity drug race as GLP-1 trial halts - Yahoo Finance

Apr 14, 2025
pulisher
Apr 14, 2025

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Cerevel Therapeutics Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Apr 14, 2025
pulisher
Apr 14, 2025

Health Care Up on Defensive DemandHealth Care Roundup - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Obesity Drug Developers Rise on M&A Hopes After Pfizer Setback - Bloomberg.com

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer halts development of weight loss pill after liver injury report - KFXL

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our Valuation - Morningstar

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer Abandons Obesity Pill After Liver Injury in Setback - Bloomberg

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer Halts Development of Oral Obesity Drug Danuglipron After Safety Review - Mega Doctor News

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer ends development of weight-loss pill after patient's liver injury - upi.com

Apr 14, 2025
pulisher
Apr 14, 2025

Thoracic Radiculopathy Market Is Booming Worldwide 2025-2032 | Pfizer Inc.,Johnson Johnson (DePuy Synthes) - openPR.com

Apr 14, 2025
pulisher
Apr 14, 2025

Is Pfizer Stock (PFE) Worth Buying After Its Weight Loss Pill Failure? - The Globe and Mail

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer’s Danuglipron Is Done, Sparking M&A Speculation - insights.citeline.com

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer: Discontinuation of Obesity Drug Candidate Danuglipron Has No Effect on Our $42 Valuation - Morningstar

Apr 14, 2025
pulisher
Apr 14, 2025

PFIZER INC : Receives a Buy rating from Jefferies - MarketScreener

Apr 14, 2025
pulisher
Apr 14, 2025

Pfizer, Inc. (PFE) Stock Forecasts - Yahoo Finance

Apr 14, 2025

Pfizer Inc (PFE) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
drug_manufacturers_general SNY
$50.56
price down icon 0.08%
$104.88
price down icon 0.76%
$282.64
price down icon 4.29%
drug_manufacturers_general MRK
$76.46
price down icon 2.46%
drug_manufacturers_general NVS
$109.58
price down icon 0.32%
大文字化:     |  ボリューム (24 時間):